Cargando…

Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment

Cardiac side effects associated with immune checkpoint inhibitors (ICIs) are an uncommon but serious complication with a relatively high mortality. We experienced a case of cardiomyopathy induced by nivolumab. Echocardiography showed diffuse hypo-kinesis of the left ventricular cardiac wall and a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Samejima, Yumiko, Iuchi, Atsuhiko, Kanai, Tomohiro, Noda, Yoshimi, Nasu, Shingo, Tanaka, Ayako, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Harada, Hiroshi, Ezumi, Akira, Ueda, Kayo, Kawahara, Kunimitsu, Hirashima, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492128/
https://www.ncbi.nlm.nih.gov/pubmed/32448839
http://dx.doi.org/10.2169/internalmedicine.4550-20
_version_ 1783582324718305280
author Samejima, Yumiko
Iuchi, Atsuhiko
Kanai, Tomohiro
Noda, Yoshimi
Nasu, Shingo
Tanaka, Ayako
Morishita, Naoko
Suzuki, Hidekazu
Okamoto, Norio
Harada, Hiroshi
Ezumi, Akira
Ueda, Kayo
Kawahara, Kunimitsu
Hirashima, Tomonori
author_facet Samejima, Yumiko
Iuchi, Atsuhiko
Kanai, Tomohiro
Noda, Yoshimi
Nasu, Shingo
Tanaka, Ayako
Morishita, Naoko
Suzuki, Hidekazu
Okamoto, Norio
Harada, Hiroshi
Ezumi, Akira
Ueda, Kayo
Kawahara, Kunimitsu
Hirashima, Tomonori
author_sort Samejima, Yumiko
collection PubMed
description Cardiac side effects associated with immune checkpoint inhibitors (ICIs) are an uncommon but serious complication with a relatively high mortality. We experienced a case of cardiomyopathy induced by nivolumab. Echocardiography showed diffuse hypo-kinesis of the left ventricular cardiac wall and a significant decrease in the ejection fraction, like dilated cardiomyopathy. The myocardial biopsy showed non-inflammatory change; cardiac function gradually improved after treatment of acute heart failure without a corticosteroid. Although non-inflammatory left ventricular dysfunction induced by ICIs is rare, it is a reported cardiovascular toxicity. Physicians should consider this complication when treating patients with ICIs for malignant diseases.
format Online
Article
Text
id pubmed-7492128
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-74921282020-09-23 Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment Samejima, Yumiko Iuchi, Atsuhiko Kanai, Tomohiro Noda, Yoshimi Nasu, Shingo Tanaka, Ayako Morishita, Naoko Suzuki, Hidekazu Okamoto, Norio Harada, Hiroshi Ezumi, Akira Ueda, Kayo Kawahara, Kunimitsu Hirashima, Tomonori Intern Med Case Report Cardiac side effects associated with immune checkpoint inhibitors (ICIs) are an uncommon but serious complication with a relatively high mortality. We experienced a case of cardiomyopathy induced by nivolumab. Echocardiography showed diffuse hypo-kinesis of the left ventricular cardiac wall and a significant decrease in the ejection fraction, like dilated cardiomyopathy. The myocardial biopsy showed non-inflammatory change; cardiac function gradually improved after treatment of acute heart failure without a corticosteroid. Although non-inflammatory left ventricular dysfunction induced by ICIs is rare, it is a reported cardiovascular toxicity. Physicians should consider this complication when treating patients with ICIs for malignant diseases. The Japanese Society of Internal Medicine 2020-05-23 2020-08-15 /pmc/articles/PMC7492128/ /pubmed/32448839 http://dx.doi.org/10.2169/internalmedicine.4550-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Samejima, Yumiko
Iuchi, Atsuhiko
Kanai, Tomohiro
Noda, Yoshimi
Nasu, Shingo
Tanaka, Ayako
Morishita, Naoko
Suzuki, Hidekazu
Okamoto, Norio
Harada, Hiroshi
Ezumi, Akira
Ueda, Kayo
Kawahara, Kunimitsu
Hirashima, Tomonori
Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
title Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
title_full Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
title_fullStr Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
title_full_unstemmed Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
title_short Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
title_sort development of severe heart failure in a patient with squamous non-small-cell lung cancer during nivolumab treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492128/
https://www.ncbi.nlm.nih.gov/pubmed/32448839
http://dx.doi.org/10.2169/internalmedicine.4550-20
work_keys_str_mv AT samejimayumiko developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT iuchiatsuhiko developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT kanaitomohiro developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT nodayoshimi developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT nasushingo developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT tanakaayako developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT morishitanaoko developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT suzukihidekazu developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT okamotonorio developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT haradahiroshi developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT ezumiakira developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT uedakayo developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT kawaharakunimitsu developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment
AT hirashimatomonori developmentofsevereheartfailureinapatientwithsquamousnonsmallcelllungcancerduringnivolumabtreatment